Versiti - Christian Kastrup, PhD | Versiti Blood Research Institute

Christian Kastrup, PhD

 Christian   Christian  profile

Christian Kastrup, PhD

Senior Investigator and Co-Program Leader

Transfusion Medicine, Vascular Biology & Cell Therapy

Department of Surgery, Division of Trauma and Acute Care Surgery
Departments of Biochemistry, Biomedical Engineering, and Pharmacology and Toxicology
Medical College of Wisconsin

Education and Training

Postdoctoral Training
Massachusetts Institute of Technology
Robert Langer Lab, Department of Chemical Engineering; 2011

Doctoral Training
PhD, Chemistry (Rustem F. Ismagilov, Supervisor)
University of Chicago, 2008 

Christian Kastrup leads a group of biochemists, engineers and surgical residents working to gain a deeper understanding of how blood clotting is regulated and can be controlled therapeutically. Severe hemorrhage is a leading cause of death for those aged 1 to 46 years, while thrombosis is a major contributor to death and disability with age. We use proteins and cells naturally involved in blood clotting to develop novel technologies for addressing unmet needs in controlling severe bleeding and preventing unwanted clotting.

The research in our lab is focused on these questions:

  1. What new technologies are needed to halt bleeding in the most severe cases of hemorrhage?
  2. Can platelets be genetically modified to enhance their hemostatic activity, or perform new therapeutic functions?
  3. Can clot stability be altered to treat hemorrhage or thrombosis?
  4. Do soil and microbes in wounds influence severe bleeding?

We use a variety of biochemical assays, RNA biotechnology, biomaterial and lipid nanoparticle synthesis, imaging, patient blood, microfluidics and human blood, and small and large animal models to answer these questions.

Controlling clot stability to regulate hemostasis using RNA-based gene therapy

During hemorrhage, fibrin is covalently crosslinked to itself and the vessel wall to form a meshwork that seals the wound. If this meshwork is not stably linked to the vessel wall, the wound is not effectively sealed, leading to re-bleeding. This process is mediated by coagulation factor XIIIa (FXIIIa), a transglutaminase enzyme found in platelets and blood. We are currently exploring the role of FXIII, fibrinogen, and other modulators of clot degradation in severe hemorrhage. To do this, we are continuing to develop novel RNA therapies utilizing lipid nanoparticles and mRNA, siRNA, and gene editing components.

We are also utilizing these RNA gene therapies to understand and control thrombosis. Thrombosis is currently treated with anticoagulants that target events upstream of fibrin crosslinking to prevent additional clots from forming in the patient. However, these carry the risk of unwanted bleeding. We hypothesized, and are now testing, that a safer approach is to instead inhibit the stability of fibrin, which would allow an initial plug to form and seal the wound, but also increase the susceptibility of the clot to degradation.

Propelling therapeutics deep into wounds

Severe hemorrhage can be triggered by trauma, surgery, or childbirth, and requires timely treatment with blood products and hemostatic agents to stop the blood loss. The most severe cases of hemorrhage are characterized by a widespread failure of the body’s blood clotting system, and bleeds can rapidly get out of control. Hemostatic agents are often applied topically into wounds to stop bleeding, but current agents are often ineffective in severe hemorrhage because they are flushed out of the wound by high blood flow.

To address this challenge, we have developed microparticles that propel upstream through blood and deliver therapeutics deep into wounds. These microparticles, loaded with a powerful pro-coagulant enzyme, thrombin, successfully reduced blood loss and mortality in small and large animal models of bleeding in trauma, surgery and endoscopy. These hemostatic products are being translated in collaboration with commercial and military partners.

Enhancing the function of platelets and megakaryocytes

Platelets are small, anucleate blood cells essential for hemostasis. In response to vascular damage, platelets activate and aggregate to form a plug to seal the wound and prevent blood loss. As part of this process, activated platelets release molecules that promote clot formation in a localized manner. 

Platelet transfusions are used to stop or prevent bleeding, but  are often ineffective during the most severe cases of hemorrhage when platelets become dysfunctional and their contribution to hemostasis is lost. We are developing ways to enhance the natural procoagulant function of platelets to improve their hemostatic efficacy.

We have developed an approach to load nucleic acids and proteins into platelets using lipid nanoparticles (LNPs). We have demonstrated that platelets loaded with thrombin formed clots significantly faster and stronger than un-modified platelets, even in blood plasma from patients with clotting defects. We are now exploring whether we can further extend the therapeutic function of platelets by using LNPs to deliver mRNA to the platelets. We are also investigating whether LNPs can deliver therapeutics to megakaryocytes, the precursor cells to platelets, to modify platelet function.

Investigating new mechanisms for controlling clotting

Coagulation is controlled by a complex network of reactions that were first described over 50 years ago. Research over the decades has led to a better understanding of the biochemistry of the coagulation network, yet questions still remain about aspects of blood clotting. Humans deficient in coagulation factor XII (FXII) do not appear to bleed spontaneously or excessively after trauma, leading to a debate over its role in blood clotting. FXII is activated by silicates, a major component of soil, to clot blood in vitro. Interestingly, FXII is  conserved in land-dwelling animals, but not in animals that do not live on soil, such as marine mammals. We therefore asked the question, is soil a physiological activator of FXII? If so, then FXII may have roles in blood clotting that have never before been characterized, and we are exploring these.

  • DoD US Army W81XWH-20-S-CRRP "Minimally-Invasive Device and Bioabsorbable Hemostatic Powder for Managing Non-Compressible Torso Hemorrhage" Role: PI (2021-2024)
  • DoD US Army W81XWH-19-S-CCC1 "Optimizing a Gauze Dressing that Effectively Delivers Tranexamic Acid, Thrombin and Calcium for Severe Hemorrhage in Multi-Domain Operations" Role: PI (2020-2024)
  • DoD US Army W81XWH-19-PRMRP-IIRA "Enhancing Transfusable Platelets for Hemorrhage Control using Liposomal Transfection" Role: PI (2020-2024)
  • DoD US Army HT942523C0095-JW220021 "Evaluating the safety and ease of use of CounterFlow Hemostatic Gauze for Extreme Cold Environments". Role: PI (2023-2026)
  • NIH R01HL166382-01A1 "Understanding and Controlling the Contribution of Fibrinolysis to Bleeding Using a Long-Acting Antifibrinolytic RNA Therapy". Role: PI (2023-2028)

Dr. Katherine Badior
Research Scientist I

Dr. Mitchell Dyer
Adjunct Associate Investigator

Rachel Dziekan
Student Researcher, Wisconsin Lutheran College

Michael England 
Project Specialist 

Mikayla Ettmayer
Animal Technician 

Francesca Ferraresso
Graduate Student, Biochemistry and Molecular Biology

Megan Gehl 
Research Trainee, The University of Notre Dame

Dr. Laura Ketelboeter
Research Scientist II

Dr. Manoj Paul
Postdoctoral Fellow

Noah Peng
Graduate Student, Biochemistry, Medical College of Wisconsin

Dr. Monica Seadler
Surgical Resident, Medical College of Wisconsin

Chad Skaer
Research Technologist II

Dr. Halen Turner
Surgical Resident, Medical College of Wisconsin

Dr. Steven Vitullo
Research Program Administrator

Youjie Zhang
Graduate Student, Biomedical Engineering, MCW-Marquette Joint Program 

Click Here for a full list of publications from Dr. Christian Kastrup

Selected Publications
  1. Cau MF, Ferraresso F, Seadler M, Badior K, Zhang Y, Ketelboeter LM, Rodriguez GG, Chen T, Ferraresso M, Wietrzny A, Robertson M, Haugen A, Cullis PR, de Moya M, Dyer M, Kastrup CJ. siRNA-mediated reduction of a circulating protein in swine using lipid nanoparticles. Mol Ther Methods Clin Dev. 2024 Apr 27;32(2):101258. doi: 10.1016/j.omtm.2024.101258. PMID: 38779336; PMCID: PMC11109470.
  2. Ferraresso F, Leung J, Kastrup CJ. RNA therapeutics to control fibrinolysis: review on applications in biology and medicine. J Thromb Haemost. 2024 Apr 24:S1538-7836(24)00224-1. doi: 10.1016/j.jtha.2024.04.006. Epub ahead of print. PMID: 38663489.
  3. Strilchuk AW, Hur WS, Batty P, Sang Y, Abrahams SR, Yong ASM, Leung J, Silva LM, Schroeder JA, Nesbitt K, de Laat B, Moutsopoulos NM, Bugge TH, Shi Q, Cullis PR, Merricks EP, Wolberg AS, Flick MJ, Lillicrap D, Nichols TC, Kastrup CJ. Lipid nanoparticles and siRNA targeting plasminogen provide lasting inhibition of fibrinolysis in mouse and dog models of hemophilia A. Sci Transl Med. 2024 Feb 21;16(735):eadh0027. doi: 10.1126/scitranslmed.adh0027. Epub 2024 Feb 21. PMID: 38381848.
  4. Leung J, Strong C, Badior KE, Robertson M, Wu X, Meledeo MA, Kang E, Paul M, Sato Y, Harashima H, Cap AP, Devine DV, Jan E, Cullis PR, Kastrup CJ, "Genetically Engineered Transfusable Platelets using mRNA-Lipid Nanoparticles." Science Advances2023 Dec;9(48):eadi0508. doi: 10.1126/sciadv.adi0508. Epub 2023 Dec 1.
  5. Ali-Mohamad N., Cau M., Zenova V., Baylis JR., Beckett A., McFadden A., Donnellan F., Kastrup CJ, "Self-propelling thrombin powder enables hemostasis with no observable rebleeding or thrombosis over three days in a porcine model of upper gastrointestinal bleeding." Gastrointestinal Endoscopy.2023 Aug;98(2):245-248. doi: 10.1016/j.gie.2023.04.007.
  6. Juang LJ, Hur WS, Silva L, Strilchuk A, Francisco B, Leung J, Groeneveld D, La Prairie B, Chun E, Cap A, Luyendyk J, Palumbo J, Cullis P, Bugge T, Flick M, Kastrup CJ, “Suppression of fibrin(ogen)-driven pathologies through controlled knockdown by lipid nanoparticle delivery of siRNA”, Blood, In Press 2021-12.
  7. Silva LM, Doyle AD, Greenwell-Wild T, Dutzan N, Tran CL, Abusleme L, Juang LJ, Chun EM, Lum AG, Agler CS, Zuazo C, Sibree M, Jani P, Kram V, Martin D, Moss K, Lionakis M, Castellino FJ, Kastrup CJ, Flick MJ, Divaris K, Bugge TH, Moutsopoulos NM. “Fibrin is a critical regulator of neutrophil effector function at mucosal barriers” Science, Published 2021-12-23.
  8. Leung J, Cau M, Kastrup CJ, “Emerging gene therapies for enhancing the hemostatic potential of platelets” Transfusion, 2021, 2021;61:S275–S285.
  9. Strilchuk AW, Meixner SC, Leung J, Safikhan NS, Kulkarni JA, Russell HM, van der Meel R, Sutherland MR, Owens AP, Palumbo JS, Conway EM, Pryzdial ELG, Cullis PR, Kastrup CJ, “Sustained Depletion of FXIIIA by Inducing Acquired FXIIIB Deficiency in Mice”, Blood, 2020, 136 (25): 2946–2954.
  10. Juang LJ, Mazinani N, Novakowski SK, Prowse ENP, Haulena M, Gailani D, Lavkulich L, Kastrup CJ. “FXII Contributes to Hemostasis when Activated by Soil in Wounds”, Blood Advances, 2020, 4(8):1737-1745.
Thrombosis & Hemostasis
We study the properties of blood that cause it to clot. Our findings help to treat diseases that cause blood clots or excessive bleeding.
Join Versiti Blood Research Institute
Versiti Blood Research Institute, located in Milwaukee, Wisconsin, includes basic and clinical researchers in a variety of blood health fields.
Our Investigators
Browse our Investigators, Emeritus Investigators, and other members of the Blood Research Institute.
Versiti Blood Research Institute
Versiti Blood Research Institute investigators study blood disorders like hemophilia, blood cancers like leukemia, and other blood diseases.